In Q4 2024, Deep Track Capital held 56 positions worth $2.5B. They initiated 9 new positions and exited 55. Their largest holding was DVAX ($227.2M). Portfolio value shrank -16.7% versus the prior quarter.
Frequently asked questions
What stocks did Deep Track Capital own in Q4 2024?
Deep Track Capital held 56 biotech stocks in their 13F portfolio in Q4 2024. Their top positions include DVAX, GH, ITCI, IMVT, APLS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deep Track Capital's portfolio worth in Q4 2024?
Deep Track Capital's tracked biotech portfolio was worth $2.5B across 56 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did Deep Track Capital buy in Q4 2024?
Deep Track Capital initiated 9 new positions in Q4 2024, including HRMY, SEPN, CLDX, BBIO, GLPGF and 4 more. They also increased 19 existing positions.
What did Deep Track Capital sell in Q4 2024?
Deep Track Capital fully exited 55 positions in Q4 2024, including QURE, NKTX, EXEL, DCPH, BIIB and 50 more. They also trimmed 20 existing positions.
Is Deep Track Capital a biotech fund?
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Want AI analysis, insider signals, and catalyst overlays for Deep Track Capital?
View latest Deep Track Capital portfolio →